Evidence map›Paper›PMID 33471962›Full record

ArticleESC heart failure2021

Persistent mitral regurgitation after left ventricular assist device: a clinical conundrum.

Jose B Cruz Rodriguez, Arka Chatterjee, Salpy V Pamboukian, Jose A Tallaj, Joanna Joly, Andrew Lenneman, Sudeep Aryal, Charles W Hoopes, Deepak Acharya, Indranee Rajapreyar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Tricuspid surgery at the time of LVAD implant: A critique.Frontiers in cardiovascular medicine · 2022
    Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jose B Cruz RodriguezDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Arka ChatterjeeDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Salpy V PamboukianDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Jose A TallajDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Joanna JolyDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Andrew LennemanDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Sudeep AryalDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
Charles W HoopesDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Deepak AcharyaDivision of Cardiovascular Diseases, University of Arizona, Tucson, AZ, USA.
Indranee RajapreyarDivision of Cardiovascular Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 311, Birmingham, AL, 35233, USA.
University of Alabama at Birmingham · USTexas Tech University · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPersistent mitral valve regurgitation (MR) after continuous flow left ventricular assist device implantation (cfLVAD) is associated with pulmonary hypertension and right ventricular failure with variable effects on survival across published studies. The aim of this study is to determine the incidence and predictors of persistent MR at 6-month follow-up after cfLVAD implantation and its impact on survival, haemodynamics, right ventricular function, and morbidity. METHODS AND

resultsWe performed a retrospective review of all adult cfLVAD recipients from January 2012 to June 2017 at a single tertiary university hospital with follow-up until April 2019. Primary outcome was to compare survival between patients with no-to-mild compared with persistent moderate-to-severe MR at 6 months. Secondary outcomes included right heart failure (RHF), length of stay, re-hospitalizations, and composite of death, transplant, and pump exchange during the length of follow-up. Final analytic sample was 111 patients. The incidence of persistent moderate or severe MR at 6 months was 26%. Significant predictors of persistent MR at 6 months were left atrium dimension and volume. The group with persistent moderate-to-severe MR at 6 months had higher incidence of RHF at 6 months (45% vs. 25%, P = 0.04). There was no difference in survival at 1 year between the groups (no-to-mild MR 85.5%, moderate-to-severe MR 87.9%, Wilcoxon P-value = 0.63). There was no difference in re-hospitalizations, length of stay, composite of death, transplant, or pump exchange during the length of follow-up between the comparison groups.

conclusionsPersistent moderate-to-severe MR after cfLVAD implantation is present in one fourth of patients and is associated with increased incidence of RHF, higher mean pulmonary pressure, and pulmonary capillary wedge pressure with no effect on 1 year survival. Increased left atrium size was associated with persistent moderate-to-severe MR at 6 months.

Indexed as

Heart-Assist DevicesMitral Valve InsufficiencyAdultHumansRetrospective StudiesTreatment OutcomeVentricular Function, RightContinuous flow ventricular assist deviceMitral regurgitation

Identifiers

PMID33471962
PMCPMC8006607
OpenAlexW3123906289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.